CMV infection after UCBT by risk (scoring) group in both cohorts (N = 1278)
| Derivation cohort (n = 893) . | Validation cohort (n = 385) . | ||||||
|---|---|---|---|---|---|---|---|
| Risk group . | n (%) . | % CMV infection . | P value . | Risk group . | n (%) . | % CMV infection . | P value . |
| Low (0) | 182 (20.4) | 3.8 | <.0001 | Low (0) | 83 (21.6) | 1.2 | <.0001 |
| Intermediate (1-26) | 393 (44.0) | 17.0 | Intermediate (1-26) | 161 (41.8) | 12.4 | ||
| High (27-29) | 318 (35.6) | 52.8 | High (27-29) | 141 (36.6) | 53.9 | ||
| Derivation cohort (n = 893) . | Validation cohort (n = 385) . | ||||||
|---|---|---|---|---|---|---|---|
| Risk group . | n (%) . | % CMV infection . | P value . | Risk group . | n (%) . | % CMV infection . | P value . |
| Low (0) | 182 (20.4) | 3.8 | <.0001 | Low (0) | 83 (21.6) | 1.2 | <.0001 |
| Intermediate (1-26) | 393 (44.0) | 17.0 | Intermediate (1-26) | 161 (41.8) | 12.4 | ||
| High (27-29) | 318 (35.6) | 52.8 | High (27-29) | 141 (36.6) | 53.9 | ||
Data were missing from 128 recipients.